Roth Capital Predicts CapsoVision's Q2 Earnings (NASDAQ:CV)

Key Points

• Roth Capital has projected CapsoVision's Q2 2025 earnings per share at ($0.11) and maintains a "Strong-Buy" rating with a price target of $6.00.
• Estimates from Roth Capital indicate that CapsoVision will continue to post negative earnings in upcoming quarters, with expected FY2025 earnings of ($0.49) EPS.
• CapsoVision's stock is currently trading at $4.54, with a one-year price range between $3.49 and $5.72.

CapsoVision, Inc. (NASDAQ:CV - Free Report) - Equities research analysts at Roth Capital issued their Q2 2025 EPS estimates for shares of CapsoVision in a research note issued to investors on Monday, July 28th. Roth Capital analyst J. Wittes expects that the company will post earnings of ($0.11) per share for the quarter. Roth Capital currently has a "Strong-Buy" rating and a $6.00 target price on the stock. Roth Capital also issued estimates for CapsoVision's Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.35 EPS and FY2029 earnings at $0.58 EPS.

A number of other equities analysts have also issued reports on the stock. Wall Street Zen upgraded shares of CapsoVision to a "hold" rating in a research report on Sunday, July 13th. Benchmark assumed coverage on shares of CapsoVision in a research report on Monday, July 28th. They set a "speculative buy" rating and a $5.00 target price on the stock.

CapsoVision Stock Up 1.0%

CapsoVision stock traded up $0.04 during trading hours on Wednesday, hitting $3.91. 50,843 shares of the stock were exchanged, compared to its average volume of 124,694. CapsoVision has a 12 month low of $3.49 and a 12 month high of $5.72.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.